Zuckerman Spaeder has submitted an amicus brief opposing Merck’s legal challenge to the Drug Price Negotiation Program (DPNP), on behalf of nine healthcare and Medicare experts. The DPNP, established by the Inflation Reduction Act, gives the federal government the authority to bargain for the price of particular prescription medications, which is a crucial step in bringing down healthcare costs.
Click Here to Read More https://www.zuckerman.com/news/press-release/leading-healthcare-experts-oppose-lawsuit-challenging-medicares-drug-price-negotiation-program
